A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bevacizumab
/ administration & dosage
Carboplatin
/ administration & dosage
Carcinoma
/ diagnosis
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
/ diagnosis
Neoplasm Staging
Paclitaxel
/ administration & dosage
Progression-Free Survival
Uterine Cervical Neoplasms
/ diagnosis
Young Adult
Chemotherapy
Metastatic or recurrent cervical carcinoma
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
06
03
2021
accepted:
07
05
2021
pubmed:
22
5
2021
medline:
15
12
2021
entrez:
21
5
2021
Statut:
ppublish
Résumé
To assess the efficacy and safety of dose-dense weekly paclitaxel plus carboplatin (ddTC) with or without bevacizumab compared to conventional, tri-weekly paclitaxel plus carboplatin (cTC) with or without bevacizumab, in metastatic or recurrent cervical carcinoma not amenable to curative local therapy. Patients were randomly assigned to either the cTC or ddTC arm. The cTC regimen was paclitaxel 175 mg/m jRCTs031180007. In total, 122 patients were randomly assigned to either the cTC arm (cTC + bevacizumab: 32; cTC:29) or the ddTC arm (ddTC+bevacizumab: 30; ddTC:31). The RR for patients on cTC + bevacizumab was 67.9%, and for patients on ddTC+bevacizumab 60.7%, cTC: 55.2%, and ddTC: 50.0%. The study did not meet the primary endpoint of phase II portion. Dose-dense, weekly paclitaxel plus carboplatin is not promising for metastatic or recurrent cervical carcinoma.
Identifiants
pubmed: 34016453
pii: S0090-8258(21)00403-0
doi: 10.1016/j.ygyno.2021.05.007
pii:
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Types de publication
Clinical Trial, Phase II
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
292-298Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None of the authors reports that they have any conflict of interest to disclose.